PRIMARY STUDY
Modulation of CB1 and CB2 receptors and endocannabinoid activity in inflammatory bowel diseases
Key Findings: This study found a strong positive correlation between the relative expression of CB1 and nociceptin receptor (NOP) receptors, as well as CB2 and NOP receptors, in Crohn's disease. Several endocannabinoids were significantly increased.
Type of Study: Clinical Trial
Study Result: Positive
Research Location(s): Canada, Italy, Poland
Year of Pub: 2024
Cannabinoids Studied: Endocannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2
Citation: Wolyniak M, Wlodarczyk M, Piscitelli F, Verde R, Di Marzo V, Mokrowiecka A, Malecka-Wojciesko E, Fabisiak A. Modulation of CB1 and CB2 receptors and endocannabinoid activity in inflammatory bowel diseases. J Physiol Pharmacol. 2024 Oct;75(5). doi: 10.26402/jpp.2024.5.08. Epub 2024 Dec 4. PMID: 39652903.
